Inventor · disambiguated record
Laurence Elias
Also filed as: ELIAS LAURENCE
17 granted patents·21 pending applications·313 citations·filing 2006–2024
96Inventor score
Top patents by PatentIndex Score
38 records- 0198US9125889B2Use of inhibitors of Bruton's tyrosine kinase (Btk)PHARMACYCLICS INC·Filed 2014·Granted Sep 8, 2015·63 cites·2 claims
- 0298US8999999B2Use of inhibitors of Bruton's tyrosine kinase (Btk)PHARMACYCLICS INC·Filed 2013·Granted Apr 7, 2015·66 cites·18 claims
- 0397US9107924B2Inhibitors of Bruton'S tyrosine kinase for the treatment of solid tumorsPHARMACYCLICS INC·Filed 2013·Granted Aug 18, 2015·40 cites·3 claims
- 0496US10016435B2Use of inhibitors of Bruton's tyrosine kinase (Btk)PHARMACYCLICS LLC·Filed 2017·Granted Jul 10, 2018·12 cites·8 claims
- 0596US10004746B2Use of inhibitors of Bruton's tyrosine kinase (Btk)PHARMACYCLICS LLC·Filed 2017·Granted Jun 26, 2018·9 cites·30 claims
- 0696US9814721B2Use of inhibitors of bruton'S tyrosine kinase (BTK)PHARMACYCLICS LLC·Filed 2016·Granted Nov 14, 2017·14 cites·11 claims
- 0796US9801883B2Use of inhibitors of bruton's tyrosine kinase (Btk)PHARMACYCLICS LLC·Filed 2016·Granted Oct 31, 2017·11 cites·31 claims
- 0895US9801881B2Use of inhibitors of bruton's tyrosine kinase (BTK)PHARMACYCLICS LLC·Filed 2013·Granted Oct 31, 2017·13 cites·18 claims
- 0995US8012465B2Methods for treating renal cell carcinomaNOVARTIS VACCINES & DIAGNOSTIC·Filed 2009·Granted Sep 6, 2011·45 cites·18 claims
- 1094US10004745B2Use of inhibitors of Bruton'S tyrosine kinase (Btk)PHARMACYCLICS LLC·Filed 2016·Granted Jun 26, 2018·7 cites·7 claims
- 1194US9415050B2Methods for the treatment of HER2 amplified cancerPHARMACYCLICS LLC·Filed 2014·Granted Aug 16, 2016·17 cites·21 claims
- 1291US9795605B2Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumorsPHARMACYCLICS LLC·Filed 2015·Granted Oct 24, 2017·6 cites·22 claims
- 1389US2024318232A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2023·Application pending·0 cites
- 1487US2025127781A1Use of inhibitors of bruton's tyrosine kinase (btk)PHARMACYCLICS LLC·Filed 2024·Application pending·0 cites
- 1584US2022249494A1Use of inhibitors of brutons tyrosine kinase (btk)PHARMACYCLICS LLC·Filed 2022·Application pending·0 cites
- 1684US2022175785A1Use of inhibitors of brutons tyrosine kinase (btk)PHARMACYCLICS LLC·Filed 2022·Application pending·0 cites
- 1783US10016434B2Methods for the treatment of HER2 amplified cancerPHARMACYCLICS LLC·Filed 2017·Granted Jul 10, 2018·2 cites·14 claims
- 1883US8877723B2Method for identification of sensitivity of a patient to telomerase inhibition therapyHARLEY CALVIN B·Filed 2009·Granted Nov 4, 2014·4 cites·17 claims
- 1982US9724349B2Methods for the treatment of HER2 amplified cancerPHARMACYCLICS LLC·Filed 2016·Granted Aug 8, 2017·2 cites·11 claims
- 2082US2023114322A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2022·Application pending·0 cites
- 2180US2022325327A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2021·Application pending·0 cites
- 2278US10196677B2Method for identification of sensitivity of a patient to telomerase inhibition therapyGERON CORP·Filed 2017·Granted Feb 5, 2019·1 cites·17 claims
- 2376US9617583B2Method for identification of sensitivity of a patient to telomerase inhibition therapyGERON CORP·Filed 2014·Granted Apr 11, 2017·1 cites·10 claims
- 2476US2020276199A1Inhibitors of bruton's tyrosine kinase for the treatment of solid tumorsPHARMACYCLICS LLC·Filed 2019·Application pending·0 cites
- 2575US2021269861A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2020·Application pending·0 cites
- 2674US2021361657A1Use of inhibitors of brutons tyrosine kinase (btk)PHARMACYCLICS LLC·Filed 2020·Application pending·0 cites
- 2772US2018280395A1Use of inhibitors of bruton's tyrosine kinase (btk)PHARMACYCLICS LLC·Filed 2018·Application pending·0 cites
- 2870US2015031710A1Use of inhibitors of bruton's tyrosine kinase (btk)PHARMACYCLICS INC·Filed 2014·Application pending·0 cites
- 2970US2021145835A1Methods for the treatment of her2 amplified cancerPHARMACYCLICS LLC·Filed 2020·Application pending·0 cites
- 3068US2019382829A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2018·Application pending·0 cites
- 3167US2013310402A1Use of inhibitors of bruton's tyrosine kinase (btk)BUGGY JOSEPH J·Filed 2013·Application pending·0 cites
- 3266US2018193345A1Inhibitors of bruton's tyrosine kinase for the treatment of solid tumorsPHARMACYCLICS LLC·Filed 2017·Application pending·0 cites
- 3366US2013202611A1Use of inhibitors of bruton's tyrosine kinase (btk)BUGGY JOSEPH J·Filed 2013·Application pending·0 cites
- 3463US2012087915A1Use of inhibitors of bruton's tyrosine kinase (btk)BUGGY JOSEPH J·Filed 2011·Application pending·0 cites
- 3563US2019167687A1Methods for the treatment of her2 amplified cancerPHARMACYCLICS LLC·Filed 2018·Application pending·0 cites
- 3658US2014303191A1Use of inhibitors of bruton's tyrosine kinase (btk)PHARMACYCLICS INC·Filed 2012·Application pending·0 cites
- 3756US2017266186A1Use of inhibitors of bruton's tyrosine kinase (btk)PHARMACYCLICS LLC·Filed 2016·Application pending·0 cites
- 3851US2007014765A1Methods for treating renal cell carcinomaCHIRON CORP·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laurence Elias files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →